Medical Information Only. Always consult your healthcare provider before enrolling in any clinical trial.

NCT01558700 · ClinicalTrials.gov registry record · Phase 4

Duloxetine in Osteoarthritis (OA) Pain

A Phase 4 study of Osteoarthritis, sponsored by Northwestern University.

Completed
Registry status
Phase 4
Development phase
40
Enrollment target
1
Study location

NCT01558700 is a Phase 4 study of Osteoarthritis that has completed, run by Northwestern University. The registered enrollment target is 40 participants, below the 817-participant average among 135 other Osteoarthritis trials with a reported enrollment target (95% lower). The trial reports 1 study location across 1 state.

View on ClinicalTrials.gov ↗

View your shortlist →

The verdict

NCT01558700, a Phase 4 study of Osteoarthritis, has completed, sponsored by Northwestern University.

COMPLETED
Registry status
Phase 4
Development phase
40 participants
Enrollment target
1
Study location

Study Summary

This study aims to determine in people with knee Osteoarthritis (OA) if relief of pain after treatment with either duloxetine or placebo is associated with changes in brain anatomy.

Conditions Studied

Interventions

  • DRUG Duloxetine
  • DRUG Sugar pill

Study Locations (1)

Illinois

  • Northwestern University Feinberg School of Medicine - Chicago

Trial Details

FieldValue
Enrollment Target 40 participants
Start Date 2012-03
Est. Completion 2014-08
Phase Phase 4

Sponsor

Northwestern University

1,209 total trials

What the Registry Record Tells You About NCT01558700

The ClinicalTrials.gov registry entry for NCT01558700 describes a study currently listed as completed, categorized as Phase 4. The registered enrollment target is 40 participants, a figure that helps gauge the scale of data the investigators plan to collect, below the 817-participant average among 135 other Osteoarthritis trials with a reported enrollment target (95% lower). The listed sponsor is Northwestern University, which has 1,209 total studies on file at ClinicalTrials.gov.

The record links to 1 condition, with Osteoarthritis appearing as the primary indexed condition, and to 2 interventions - of which Duloxetine is the first listed.

NCT01558700 reports 1 study location spanning 1 distinct geographic area - top geographies include Illinois.

Frequently Asked Questions

What is clinical trial NCT01558700 about?

NCT01558700 is a clinical study titled "Duloxetine in Osteoarthritis (OA) Pain". This study aims to determine in people with knee Osteoarthritis (OA) if relief of pain after treatment with either duloxetine or placebo is associated with changes in brain anatomy.

What is the current status of trial NCT01558700?

This trial is currently completed. It is a Phase 4 study. The enrollment target is 40 participants. The study started on 2012-03. Estimated completion is 2014-08.

What conditions does trial NCT01558700 study?

This clinical trial studies the following conditions: Osteoarthritis.

What interventions are being tested in trial NCT01558700?

The interventions under investigation include: Duloxetine (DRUG), Sugar pill (DRUG).

Who is sponsoring clinical trial NCT01558700?

This trial is sponsored by Northwestern University, which has 1,209 total clinical trials registered on ClinicalTrials.gov.

Where is trial NCT01558700 being conducted?

This trial has 1 study location across Illinois. Contact the study sites directly through ClinicalTrials.gov for enrollment availability.

Similar trials for Osteoarthritis

Matched on the same primary condition, ranked to surface studies in the same phase first, then by recruiting status, no relevance scoring or editorial curation.

Data sourced from official public datasets. See our methodology for details. Retrieved and formatted by PlainTrial Editorial

Every figure on PlainTrial is rendered directly from the ClinicalTrials.gov registry, no number is typed in by an editor. This page mirrors this trial's own ClinicalTrials.gov registry record, live from the dataset. See our editorial standards & corrections policy, the methodology behind these numbers, or report a data error.